NEW YORK, April 23, 2026

Biotia announced the publication of a pivotal clinical validation study in the Microbiology Spectrum journal, highlighting the performance of its advanced next-generation sequencing (NGS) and machine learning–based diagnostic test for urinary tract infections (UTIs). The study demonstrates that Biotia’s innovative approach enables highly accurate, culture-independent detection of urogenital pathogens and antimicrobial resistance, representing a significant advancement in infectious disease diagnostics.

High Accuracy Through NGS and AI Integration

The clinical validation study evaluated 1,470 patient specimens across more than 1,600 reactions, achieving 97.2% sensitivity and 99.6% specificity, underscoring the test’s exceptional diagnostic accuracy. At the core of this performance is Biotia’s proprietary BIOTIA-DX machine learning classifier, which enhances precision by filtering out contamination and distinguishing clinically relevant pathogens from commensal organisms.

Unlike traditional culture-based methods, which often fail to detect fastidious or slow-growing organisms, this NGS-based approach provides comprehensive microbial identification directly from urine samples. Additionally, the test includes antimicrobial resistance gene profiling, enabling clinicians to make data-driven treatment decisions and select the most appropriate therapies for patients.

Transforming Diagnosis of Complex and Recurrent UTIs

Advertisement

cGxPJobs Banner

Urinary tract infections affect millions of patients globally each year, yet standard diagnostic approaches frequently fall short, particularly in recurrent or complicated cases. Conventional culture methods can be time-consuming, less sensitive, and limited in detecting diverse pathogens, often leading to misdiagnosis or delayed treatment.

Biotia’s BIOTIA-ID Urine Test, developed as a laboratory-developed test (LDT) and approved by New York State, addresses these limitations by delivering rapid, accurate, and comprehensive results. By enabling detection of a broader range of bacterial and fungal pathogens, the test improves clinical confidence and diagnostic clarity, ultimately enhancing patient outcomes and reducing treatment delays.

Advancing Precision Medicine in Infectious Diseases

The integration of metagenomic sequencing and artificial intelligence represents a transformative shift toward precision medicine in infectious disease management. Biotia’s platform provides clinicians with actionable insights into pathogen identity and resistance patterns, supporting targeted antimicrobial therapy and improved antimicrobial stewardship. This is particularly important in the context of rising antimicrobial resistance, where accurate diagnostics are essential to avoid inappropriate or ineffective treatments.

The publication of this study reinforces the growing role of clinical metagenomics in modern healthcare, offering a more comprehensive and scalable alternative to traditional diagnostic methods. By combining advanced sequencing technologies with AI-driven analytics, Biotia is enabling a deeper understanding of complex infections, paving the way for more personalized and effective treatment strategies.

As healthcare systems continue to prioritize early and accurate diagnosis, innovations like Biotia’s NGS-based test are expected to play a critical role in improving infectious disease management worldwide. The company’s commitment to scientific rigor, clinical validation, and technological innovation positions it at the forefront of next-generation diagnostics, helping clinicians move beyond conventional limitations and deliver high-quality, patient-centered care.

Source: Biotia press release